2-hydroxybenzoyl-N-(4-methylsulfinyl)thiazol-2-yl amide | 1259483-81-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxybenzoyl-N-(4-methylsulfinyl)thiazol-2-yl amide
• 英文别名: 2-hydroxy-N-[4-(methylsulfinyl)-1,3-thiazol-2-yl]benzamide；2-hydroxy-N-(4-methylsulfinyl-1,3-thiazol-2-yl)benzamide
• CAS: 1259483-81-2
• 化学式: C₁₁H₁₀N₂O₃S₂
• 分子量: 282.344
• InChiKey: OETRJUMTRHUYHI-UHFFFAOYSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  邻乙酰水杨酰氯 在 盐酸 、 oxone 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 18.15h， 生成 2-hydroxybenzoyl-N-(4-methylsulfinyl)thiazol-2-yl amide
  参考文献：
  名称：

  ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS

  摘要：

  描述了一类新的烷基亚磺酰基噻唑酮化合物。这些化合物对肝炎病毒表现出强大的活性。

  公开号：

  US20120108591A1

文献信息

• Alkylsulfinyl-substituted thiazolide compounds
  申请人：Semple J. Edward

  公开号：US08772502B2

  公开（公告）日：2014-07-08

  A new class of alkylsulfinyl thiazolides is described. These compounds show strong activity against hepatitis viruses.

  描述了一种新型的烷基亚磺酰噻唑类化合物。这些化合物对乙型肝炎病毒表现出强烈的活性。
• THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS
  申请人：Romark Laboratories, L.C.

  公开号：EP3895706A1

  公开（公告）日：2021-10-20

  This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.

  本发明涉及通过使用式 I 化合物抑制流感病毒 HA 成熟过程来治疗和预防流感感 染的方法，还涉及由式 I 化合物和其他制剂组成的治疗和预防流感感染的组合物。
• Compounds and methods for treating influenza
  申请人：Romark Laboratories L.C.

  公开号：US10363243B2

  公开（公告）日：2019-07-30

  This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.

  本发明涉及通过使用式 I 化合物抑制流感病毒 HA 成熟过程来治疗和预防流感感 染的方法，还涉及由式 I 化合物和其他制剂组成的治疗和预防流感感染的组合物。
• Thiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication
  作者：Andrew V. Stachulski、Chandrakala Pidathala、Eleanor C. Row、Raman Sharma、Neil G. Berry、Alexandre S. Lawrenson、Shelley L. Moores、Mazhar Iqbal、Joanne Bentley、Sarah A. Allman、Geoffrey Edwards、Alison Helm、Jennifer Hellier、Brent E. Korba、J. Edward Semple、Jean-Francois Rossignol

  DOI：10.1021/jm201264t

  日期：2011.12.22

  We report the activities of a number of thiazolides [2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis C virus (HCV) genotypes IA and IB, using replicon assays. The structure activity relationships (SARs) of thiazolides against HCV are less predictable than against hepatitis B virus (HBV), though an electron-withdrawing group at C(5') generally correlates with potency. Among the related salicyloylanilides, the m-fluorophenyl analogue was most promising; niclosamide and close analogues suffered from very low solubility and bioavailability. Nitazoxanide (NTZ) 1 has performed well in clinical trials against HCV. We show here that the 5'-Cl analogue 4 has closely comparable in vitro activity and a good cell safety index. By use of support vector analysis, a quantitative structure activity relationship (QSAR) model was obtained, showing good predictive models for cell safety. We conclude by updating the mode of action of the thiazolides and explain the candidate selection that has led to compound 4 entering preclinical development.
• COMPOUNDS AND METHODS FOR TREATING INFLUENZA
  申请人：Romark Laboratories, L.C.

  公开号：EP2445349B1

  公开（公告）日：2022-02-09